Melanotan-2 (MT-2): Complete Guide

Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Melanotan-2 is a synthetic melanocortin peptide that stimulates melanogenesis (tanning), sexual arousal, and appetite suppression via MC1R and MC4R receptor agonism.

Melanotan-2 (MT-2): A Comprehensive Compound Guide

Melanotan-2 (MT-2) is a synthetic melanocortin peptide that has garnered significant attention for its ability to induce skin tanning and its potential effects on sexual function and appetite. This guide provides a comprehensive overview of MT-2, covering its mechanism of action, clinical evidence, dosing protocols, side effects, and safety considerations.

What is Melanotan-2?

Melanotan-2 is a synthetic analog of the naturally occurring alpha-melanocyte-stimulating hormone (α-MSH). It is a cyclic heptapeptide that selectively binds to and activates various melanocortin receptors (MCRs) in the body, primarily MC1R and MC4R.

MC1R (Melanocortin 1 Receptor): Found predominantly on melanocytes, the cells responsible for producing melanin. Activation of MC1R leads to increased melanin synthesis, resulting in skin pigmentation (tanning).

MC4R (Melanocortin 4 Receptor): Located in the central nervous system, particularly in the hypothalamus. Activation of MC4R is implicated in the regulation of appetite, energy homeostasis, and sexual function.

Originally synthesized at the University of Arizona in the 1980s, MT-2 was developed with the aim of creating a photoprotective agent that could induce tanning without exposure to harmful UV radiation. Its subsequent discovery of other physiological effects, particularly on sexual function, expanded its research scope.

Mechanism of Action

Melanotan-2 exerts its diverse effects through the agonistic activation of melanocortin receptors.

Melanogenesis (Skin Tanning)

The primary and most well-known mechanism of action of MT-2 is its ability to stimulate melanogenesis. Upon administration, MT-2 binds to and activates MC1R on melanocytes. This activation triggers a cascade of intracellular events, including the activation of adenylate cyclase and the subsequent increase in cyclic AMP (cAMP) levels. Elevated cAMP then upregulates the expression and activity of enzymes involved in melanin synthesis, such as tyrosinase.

There are two main types of melanin:

Eumelanin: A black/brown pigment that provides significant photoprotection.

Pheomelanin: A red/yellow pigment that offers less photoprotection and can even be pro-oxidant under UV exposure.

MT-2 primarily promotes the production of eumelanin, leading to a darker, more protective tan. This mechanism is distinct from UV-induced tanning, which can also increase pheomelanin production and DNA damage. By stimulating eumelanin production, MT-2 offers a potential strategy for individuals with fair skin (Fitzpatrick skin types I and II) to achieve a tan and potentially reduce their risk of UV-induced skin damage.

Sexual Function

MT-2's effects on sexual function are mediated primarily through its agonism of MC4R in the central nervous system. Activation of MC4R in specific hypothalamic nuclei, such as the paraventricular nucleus (PVN), is known to play a crucial role in regulating sexual arousal and erectile function.

Erectile Function (Males): MT-2's activation of MC4R leads to the release of nitric oxide (NO) and other neurotransmitters in the brain, which then descend to the spinal cord and ultimately influence penile erection. This pathway is independent of the peripheral mechanisms targeted by phosphodiesterase-5 (PDE5) inhibitors (e.g., sildenafil), making MT-2 a potential alternative for individuals who do not respond to these conventional treatments. The effect is centrally mediated, meaning it acts on the brain to initiate the physiological cascade leading to erection, rather than directly on the penile tissue.

Female Sexual Dysfunction (FSD): Research suggests that MC4R activation may also play a role in female sexual arousal. By influencing central pathways involved in desire and arousal, MT-2 has shown promise in preclinical and some clinical studies for improving various aspects of female sexual function, including desire, arousal, lubrication, and orgasm.

Appetite Suppression

Another observed effect of MT-2 is appetite suppression and a potential reduction in food intake. This effect is also attributed to its agonistic activity at MC4R within the hypothalamus, a brain region critical for regulating hunger and satiety. Activation of MC4R in the arcuate nucleus and other hypothalamic areas can lead to a feeling of fullness and reduced desire to eat, potentially contributing to weight loss. This mechanism aligns with the known role of the melanocortin system in energy homeostasis.

Research and Clinical Evidence

While MT-2 has not received FDA approval for any indication, a considerable body of research, including preclinical studies and some human trials, supports its reported effects.

Tanning

Human Studies: Early clinical trials demonstrated that MT-2 effectively induces skin tanning in individuals with various skin types, including those who typically burn easily. Studies have shown that subcutaneous administration of MT-2 leads to a significant increase in skin pigmentation, often without the need for UV exposure. The tan produced by MT-2 is generally described as a natural-looking, darker tan that persists for several weeks after cessation of treatment.

Photoprotection: Research suggests that the increased eumelanin production induced by MT-2 can offer a degree of photoprotection against UV radiation, potentially reducing the risk of sunburn and DNA damage. This aspect was a primary motivation for its initial development.

Erectile Dysfunction (ED)

Clinical Trials: Several clinical trials have investigated MT-2 for the treatment of ED. These studies have shown that MT-2 can induce erections in men with psychogenic and organic ED, including those who did not respond to PDE5 inhibitors. The onset of action is typically within 30-60 minutes after subcutaneous injection, and the effect can last for several hours. The erections are often described as spontaneous and robust.

Mechanism Confirmation: The efficacy of MT-2 in ED further supports the role of MC4R in modulating erectile function, offering a novel therapeutic target beyond the traditional NO-cGMP pathway.

Female Sexual Dysfunction (FSD)

Preclinical and Early Clinical Research: While less extensively studied than ED, preliminary research, primarily with its derivative bremelanotide (PT-141), suggests that melanocortin receptor agonists can improve aspects of FSD. Studies have indicated improvements in sexual desire, arousal, and overall sexual satisfaction in women. MT-2's similar mechanism of action suggests it may also hold potential in this area, though direct clinical trials specifically for MT-2 in FSD are more limited.

Reconstitution: MT-2 is usually supplied as a lyophilized powder and must be reconstituted with bacteriostatic water.

Typical Starting Dose: For tanning, a common starting dose is 0.25 mg to 0.5 mg once daily or every other day. For sexual function, doses may range from 0.5 mg to 1 mg as needed.

Titration: Doses are typically increased gradually over several days or weeks until the desired effect is achieved or side effects become intolerable.

Maintenance Dose (Tanning): Once a desired tan is achieved, a maintenance dose of 0.25 mg to 0.5 mg once or twice a week may be sufficient to sustain the tan.

Administration Route: Subcutaneous injection, usually into the fatty tissue of the abdomen or thigh, using an insulin syringe.

Timing: For tanning, injections are often administered in the evening to mitigate acute side effects like nausea and flushing during waking hours. For sexual function, it is administered approximately 30-60 minutes before anticipated sexual activity.

Duration: Tanning protocols can last for several weeks to months, depending on the desired depth of tan. For sexual function, it is used on an as-needed basis.

Important Note: The optimal dosing regimen is highly individualized. Users often experiment to find the lowest effective dose that minimizes side effects.

Side Effects and Safety Profile

MT-2 is associated with a range of side effects, some of which can be significant. The severity and incidence of these side effects are often dose-dependent.

Common Side Effects:

Nausea: One of the most frequently reported side effects, often occurring shortly after injection. It can range from mild discomfort to severe vomiting. Starting with lower doses and injecting before bed can help manage this.

Facial Flushing: A sensation of warmth and redness, particularly in the face, is common and usually transient.

Loss of Appetite: While sometimes a desired effect, it can also lead to unintended weight loss if not managed.

Fatigue: Some users report feelings of tiredness or lethargy.

Spontaneous Erections (Males): A common and sometimes inconvenient side effect, particularly at higher doses, due to its central action on sexual function. These can occur at inappropriate times.

Increased Libido: Both males and females may experience an increase in sexual desire.

Hypertension (Transient): Some individuals may experience a temporary increase in blood pressure after administration.

Mole Changes: MT-2 can darken existing moles and freckles, and in some cases, may cause new moles to appear. There is ongoing concern about whether MT-2 could potentially increase the risk of melanoma or exacerbate existing atypical nevi. Regular skin checks by a dermatologist are highly recommended for users.

Postural Hypotension: A drop in blood pressure upon standing, leading to dizziness or lightheadedness.

Kidney Pain: Rare reports of kidney discomfort have been noted.

Gastrointestinal Distress: Beyond nausea, some users report stomach cramps or diarrhea.

Injection Site Reactions: Redness, swelling, or itching at the injection site.

Long-Term Safety:

The long-term safety profile of MT-2 is not well-established due to the lack of extensive, long-term clinical trials. Concerns remain regarding its potential impact on melanoma risk, cardiovascular health, and other systemic effects with prolonged use.

Regulatory Status

Melanotan-2 is not approved by the Food and Drug Administration (FDA) or similar regulatory bodies in most countries for human use. It is classified as a research chemical, meaning it is intended for in vitro (test tube) and in vivo (animal) research purposes only, and not for direct administration to humans.

The sale and purchase of MT-2 for human consumption are illegal in many jurisdictions. Despite this, it is widely available online and on the black market, often marketed for tanning or sexual enhancement. Users should be aware that products purchased from unregulated sources may be impure, mislabeled, or contain contaminants, posing significant health risks.

Comparison with Bremelanotide (PT-141)

Bremelanotide (PT-141) is a synthetic melanocortin peptide closely related to MT-2. It is also an analog of α-MSH and acts as an agonist at melanocortin receptors. However, there are key differences:

Receptor Selectivity: While MT-2 activates both MC1R and MC4R (among others), PT-141 is considered more selective for MC4R. This increased selectivity for MC4R is why PT-141 was specifically developed and approved (as Vyleesi®) for female sexual dysfunction, as it primarily targets the central pathways for sexual arousal with minimal melanogenesis side effects.

Clinical Approval: PT-141 (as Vyleesi®) is FDA-approved for the treatment of generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. MT-2 has no FDA approval.

Primary Use: MT-2 is predominantly used off-label for tanning and, secondarily, for sexual function. PT-141's primary clinical use is for sexual dysfunction.

Tanning Effect: MT-2 is a potent tanning agent due to its strong MC1R activation. PT-141 has a significantly reduced, if any, tanning effect due to its lower affinity for MC1R.

Side Effect Profile: Both can cause nausea and flushing. However, spontaneous erections are more pronounced with MT-2 due to its broader receptor activity. The risk of significant mole changes is also higher with MT-2.

Individuals seeking a "sunless" tan: Especially those with very fair skin (Fitzpatrick types I and II) who burn easily and struggle to tan naturally.

Males with Erectile Dysfunction: Particularly those who have not responded to conventional PDE5 inhibitors.

Individuals seeking increased libido: Both males and females, though safer and approved alternatives exist for female sexual dysfunction (e.g., PT-141).

Contraindications and Cautions:

History of Melanoma or Atypical Moles: Individuals with a personal or family history of melanoma or numerous atypical moles should strictly avoid MT-2 due to the potential risk of exacerbating or promoting skin cancer.

Cardiovascular Conditions: Individuals with heart conditions, high blood pressure, or a history of stroke should exercise extreme caution or avoid MT-2 due to potential effects on blood pressure and